[Clinical Milestone] BPM’s DNlite-IVD103 Officially Included in the 2024 Taiwan Clinical Care Guidelines for Diabetic Kidney Disease (DKD)

BPM's DNlite-IVD103 Included in the 2024  Taiwan Clinical Practice Guideline for Diabetic Kidney Disease, Ushering in a New Era of Precision Preventive Medicine.

The updated guidelines explicitly highlight that DNlite-IVD103, the world's first ELISA-based biomarker test of its kind, effectively bridges the clinical gaps left by conventional Urinary Albumin-to-Creatinine Ratio (UACR) and estimated Glomerular Filtration Rate (eGFR) tests.

Dr. Karen Tseng, Chairman and CEO of BPM, stated: "The world's leading nephrology organization, KDIGO, recommended the integration of personalized risk prediction tools in their 2024 guidelines. The inclusion of DNlite in Taiwan's updated guidelines is not only a tremendous validation of our work but also demonstrates our perfect alignment with the highest global medical consensus. We are moving full speed ahead toward establishing DNlite as the gold standard in global clinical guidelines.

Related News Links:

首款MIT納指引！新穎生醫DNlite-IVD103納入臺灣糖尿腎病臨床照護指引 環球生技

DNlite-IVD103納指引 新穎營運展望正向樂觀 工商時報

DNlite-IVD103納指引 挹注新穎生醫營運成長 MoneyDJ